zygosity or homozygosity for

HLA class II haplotypes favorable outcomes for renal cell carcinoma treated with therapy. J. Urol.

(

),

–

Evans, D., Mann, W.A., Heer, J., Michel, U., Wendt, D., Kortner, B., A., Beisiegel, U.,

Variation in the gene for human proliferator activated receptor (PPAR) does not play a major role in development of morbid obesity. Int. J. Obes. Relat. Metab. Disord.

–

Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A.M., R., Najib, J., Laville, M., Fruchart, J.C., Deeb, S., Vidal-Puig, A., J., Briggs, M.R., Staels, B., Vidal, H., Auwerx, J.,

Intriguingly, the fact that longevity is associated with an increased heterozygosity at PPARG locus is in agreement with previous finding suggesting a survival advantage for heterozygous (Gerkins et al., 1974; Altukhov and Sheremet’eva, 2000; Penn et al., 2002; Ellerhorst et al., 2003). To this regard, heterozygosity at the MHC, the highly polymorphic loci that control immunological recognition of pathogens, has been found associated with significant prolongation of survival (Penn et al., 2002; Ellerhorst et al., 2003). Indeed, loss of heterozygosity is frequent in a number of non-endocrine tumors and in a few endocrine tumors and its presence can correlate with tumor aggres- siveness and survival. (Chen et al., 2003; Ho et al., 2002). Naturally, caution must be exercised in interpreting these novel findings. In fact, some studies did not confirm a survival advantage for heterozygotes (Caruso and Candore, 2000), whereas others suggested that increased homozyg- osity contributes to human longevity (Bonafe` et al., 2001b).

In conclusion, our study demonstrated that paraoxonase Pro/Ala gene polyporphism is associated with human longevity. Such an effect is probably due to the effect of Pro/Ala polymorphism on body composition and appears to be gender specific.

Alberti, K.G.M.M., Zimmet, P.Z., for the WHO Consultation,

Definition, diagnosis and classification of diabetes mellitus and its complications. Part

: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med.

,

–

Altshuler, D., Hirschhorn, J.N., Klannemark, M., Lindgren, C.M., Vohl, M.C., Nemesh, J., Lane, C.R., Schaffner, S.F., Bolk, S., Brewer, C., Tuomi, T., Gaudet, D., Hudson, T.J., Daly, M., Groop, L., Lander, E.S.,

The common PPAR Pro

Ala polymorphism is associated with decreased risk of type

diabetes. Nat. Genet.

,

–

Altukhov, Yu.P., Sheremet’eva, V.A.,

Genomic heterozygosity and human longevity. Dokl. Biol. Sci.

(

–

),

–

Beamer, B.A., Negri, C., Yen, C.J., Gavrilova, O., Rumberger, J.M., Durcan, M.J., Yarnall, D.P., Hawkins, A.L., Griffin, C.A., Burns, D.K., Roth, J., Reitman, M., Shuldiner, A.R.,

Chromosomal localiz- ation and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (

PAR gamma) gene.

(

)

–

Penn, D.J., Damjanovich, K., Potts, W.K.,

MHC heterozygosity confers a selective advantage against multiple-strain infections. Proc. Natl Acad. Sci. USA

(

),

–

Plutzky, J.,

The potential role of peroxisome proliferator-activated receptors on inflammation in type

diabetes mellitus and athero- sclerosis. Am J Cardiol.

(

A),

J–

J. Puca, A.A., Daly, M.J., Brewster, S.J., Matise, T.C., Barrett, J., Shea- Drinkwater, M., Kang, S., Joyce, E., Nicoli, J., Benson, E., Kunkel, L.M., Perls, T.,

A genome-wide scan for linkage to human exceptional longevity identifies a locus on chromosome

Proc. Natl Acad. Sci. USA

(

),

–

Ricote, M., Li, A.C., Wilson, T.M., Kelly, C.J., Glass, C.K.,

The peroxisome proliferator-activated receptor (PPARgamma) is a negative regulator of macrophage activation. Nature

,

–

Ricote, M., Huang, J.T., Welch, J.S., Glass, C.K.,

The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of mono- cyte/macrophage function. J. Leukoc. Biol.

(

),

–

Ristow, M., Muller-Wieland, D., Pfeiffer, A., Krone, W., Kahn, C.R.,

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med.

(

),

–

Rosmond, R., Chagnon, M., Bouchard, C.,

a. The Pro

Ala PPARgamma

gene missense mutation is associated with obesity and insulin resistance in Swedish middle-aged men. Diabetes Metab. Res. Rev.

(

),

–

Rosmond, R., Chagnon, M., Bouchard, C.,

b. The Pro

Ala PPARgamma

gene missense mutation is associated with obesity and insulin resistance in Swedish middle-aged men. Diabetes Metab. Res. Rev.

(

),

–

Sambrook, J., Fritsch, E.F., Maniatis, T. (Eds.),

Molecular Cloning: A Laboratory Manual,

nd ed., Cold Spring Harbor laboratory Press, Cold Spring Harbor, New York. Schachter, F., Faure-Delanef, L., Guenot, F., Rouger, H., Froguel, P., Lesueur-Ginot, L., Cohen, D.,

Genetic associations with human longevity at the APOE and ACE loci. Nat. Genet.

(

),

–

Schneider, J., Kreuzer, J., Hamann, A., Nawroth, P.P., Dugi, K.A.,

The proline

alanine substitution in the peroxisome proliferator- activated receptor-gamma

gene is associated with lower lipoprotein lipase activity in vivo. Diabetes

(

),

–

Spiegelman, B.M.,

PPARg: adipogenic regulator and thiazolidine- dione receptor. Diabetes

,

–

Thatcher, A.R., Kannisto, V., Vaupel, J.W.,

The Forces of Mortality at Age

to

, Odense Monographs on Population Aging, vol.

Odence University Press. Valve, R., Sivenius, K., Miettinen, R., Pihlajamaki, J., Rissanen, A., Deeb, S.S., Auwerx, J., Uusitupa, M., Laakso, M.,

Two polymorphisms in the peroxisome proliferator-activated receptor-gene are associated with severe overweight among obese women. J. Clin. Endocrinol. Metab.

,

–

Yashin, A.I., De Benedictis, G., Vaupel, J.W., Tan, Q., Andreev, K.F., Iachine, I.A., Bonafe`, M., De Luca, M., Valensin, S., Carotenuto, L., Franceschi, C.,

Genes, demography and life span: the contribution of demographic data and genetic studies on ageing and longevity. Am. J. Hum. Genet.

(

),

–